What is the most likely condition in a patient with a blood glucose of 44 mg/dL, absent pulse, and unrecordable blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cardiac Arrest with Severe Hypoglycemia

This patient is most likely in cardiac arrest. The combination of blood glucose of 44 mg/dL with undetectable pulse and blood pressure indicates cardiopulmonary arrest, likely precipitated or complicated by severe hypoglycemia.

Clinical Reasoning

The clinical presentation describes:

  • Severe hypoglycemia (44 mg/dL, which is <54 mg/dL = Level 2 hypoglycemia) 1
  • Absent vital signs (no pulse, no measurable blood pressure)
  • This constellation represents cardiac arrest with concurrent severe hypoglycemia

Why Cardiac Arrest is the Primary Diagnosis

The absence of pulse and unrecordable blood pressure are pathognomonic for cardiac arrest—this is not simply severe hypoglycemia with symptoms. While hypoglycemia at 44 mg/dL can cause altered mental status, seizures, or loss of consciousness 2, 1, the complete absence of circulation indicates the patient has progressed to full cardiopulmonary arrest.

The Role of Hypoglycemia

Severe hypoglycemia is a known contributor to cardiac arrest through multiple mechanisms:

  • Proarrhythmic effects: Hypoglycemia blocks repolarizing K+ channels (HERG), causing QT prolongation and risk for torsades de pointes 3
  • Sympathetic activation: Causes calcium overload and increased arrhythmia risk 3
  • Bradycardia and heart block: Hypoglycemia can induce bradycardia, which potentiates arrhythmias 3
  • Myocardial ischemia: Can occur even without coronary obstruction 3, 4
  • Electrolyte disturbances: Epinephrine release causes hypokalemia, further increasing arrhythmia risk 4

Immediate Management Algorithm

1. Initiate CPR and ACLS Protocol (Class I, LOE B) 5

  • Begin high-quality chest compressions immediately
  • Follow standard ACLS algorithms for cardiac arrest
  • Establish advanced airway and vascular access

2. Treat Severe Hypoglycemia Simultaneously

  • Administer IV dextrose (preferred over glucagon due to faster response) 6
    • Give 25g IV dextrose (50 mL of 50% dextrose or 250 mL of 10% dextrose)
    • Avoid rapid boluses of concentrated dextrose to prevent rebound hyperkalemia and cardiac complications 6
  • If no IV access: 1 mg glucagon IM (though response is slower, taking 5-15 minutes) 2

3. Post-Resuscitation Care (if ROSC achieved)

  • Target mean arterial pressure ≥65 mm Hg using fluids and vasopressors 5
  • Glucose management: Maintain blood glucose <180 mg/dL (10 mmol/L) but avoid hypoglycemia 7, 5
    • Do NOT implement tight glucose control (80-110 mg/dL) as this increases mortality risk (Class III) 5
    • Target moderate glycemic control (144-180 mg/dL) 5
  • Monitor glucose every 1-2 hours initially 6
  • Treat any seizures if they occur post-arrest 7

Critical Pitfalls to Avoid

Do not delay CPR to treat hypoglycemia first—the absent pulse and blood pressure indicate cardiac arrest requiring immediate chest compressions. Hypoglycemia treatment should occur concurrently with resuscitation efforts.

Avoid overcorrection of glucose—rapid administration of concentrated dextrose has been associated with cardiac arrest and hyperkalemia 6. Give measured doses and recheck glucose.

Do not assume hypoglycemia alone explains the arrest—investigate other reversible causes (H's and T's of ACLS), though hypoglycemia itself may have triggered the arrest through the mechanisms described above.

Prognosis Considerations

Severe hypoglycemia (<40 mg/dL) is associated with significantly increased mortality in critically ill patients, with hospital mortality rates of 55.9% in one cohort 6. The combination with cardiac arrest further worsens prognosis. However, appropriate and timely treatment can lead to favorable outcomes even in severe cases 8.

Related Questions

In a 23‑year‑old woman who had a single unprovoked tonic‑clonic‑appearing event two months ago associated with documented hypoglycemia (capillary glucose 3.3 mmol/L) and now experiences brief conscious auras with head tremor and visual disturbances, with normal neurological examination and routine laboratory tests, what specific history questions should be asked, which investigations (e.g., EEG, brain MRI, metabolic panel, oral glucose tolerance test, continuous glucose monitoring) are indicated, how should the hypoglycemia be managed, and how should the overall work‑up be interpreted and concluded?
In a 45-year-old man with newly diagnosed diabetes presenting with nausea, vomiting, weight loss, negative insulin autoantibodies, negative islet‑cell antibodies, negative GAD‑65 antibodies, and a normal C‑peptide level, what is the most likely diagnosis?
What is the appropriate emergency management for a 54-year-old male with uncontrolled diabetes, blood glucose 365 mg/dL, four days of dizziness, nausea, vomiting, and who has missed insulin and GLP‑1 therapy for one week?
In a 68-year-old patient presenting with weakness, visual disturbances, confusion, severe hyperglycemia, mild metabolic acidosis, weakly positive urinary acetone, and a normal anion gap, which of the following statements is false?
Could a 17-month-old female presenting with polydipsia and irritability have type 1 diabetes?
Can Strattera (atomoxetine) cause urinary retention?
Should an adult with acute otitis media be treated with Keflex (cephalexin)?
What alternative antibiotic therapy is recommended for a patient with a reported amoxicillin allergy?
What is the difference between tiny pulmonary granulomata and a pulmonary nodule that effaces a vessel?
What is the appropriate treatment for impaired fasting glucose (IFG)?
What causes the marked drop in DHEA levels in a woman on high‑dose progesterone and estrogen therapy, and how should it be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.